Michael J. Duffy - Concepedia

Author

Michael J. Duffy

Also Known As

Beata Jagielska, Duffy M, Duffy, M.J. (Michael), Duffy, Michael J., G. Windbichler, Gallagher, William M., IvoMeinhold-Heerlein, Lanying Song, M DUFFY, M Duffy

353

Publications

26.4K

Citations

H-Index

133

Concepts

All Affiliations

St. Vincent's University Hospital University College Dublin Dublin City University Royal College of Surgeons in Ireland Lund University

About

Michael J. Duffy is an author at St. Vincent's University Hospital specializing in medicine, breast cancer, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	61	4.3K
2	Natural Sciences	3	3	158
3	Engineering	2	2	53
4	Health Sciences	2	2	111
5	Education	1	1	19

Michael J. Duffy

122

Publications

11.5K

Citations

H-Index

Page 1

	Year	Citations
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Catharine M. Sturgeon, Michael J. Duffy, Ulf‐Håkan Stenman, Clinical Chemistry	2008	1.1K
Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful? Michael J. Duffy Clinical Chemistry	2001	785
Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients Maxime P. Look, Wim L.J. van Putten, Michael J. Duffy, JNCI Journal of the National Cancer Institute	2002	600
Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib Neil A. O’Brien, Brigid C. Browne, Lucy Chow, Molecular Cancer Therapeutics Radiation OncologyBreast OncologySignal TransductionHer2-amplified Cell LinesSignaling Pathway	2010	334
Proteases as prognostic markers in cancer. Michael J. Duffy PubMed Tumor BiologyPrognostic BiomarkersUrokinase Plasminogen ActivatorOncologyPrognostic Markers	1996	317
CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use Michael J. Duffy, J. M. G. Bonfrer, J Kulpa, International Journal of Gynecological Cancer	2005	297
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Michael J. Duffy, David Reilly, Cathriona O'Sullivan, PubMed Tumor BiologyPrognostic BiomarkersUrologyOncologyUrokinase Plasminogen Activator	1990	285
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer György Sölétormos, Michael J. Duffy, Suher Othman Abu Hassan, International Journal of Gynecological Cancer	2015	258
Urokinase Plasminogen Activator and Its Inhibitor, PAI-1, as Prognostic Markers in Breast Cancer: From Pilot to Level 1 Evidence Studies Michael J. Duffy Clinical Chemistry	2002	221
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers Catharine M. Sturgeon, Michael J. Duffy, Barry R Hofmann, Clinical Chemistry	2010	211

Page 1